Research Paper|Volume 15, Issue 22|pp 12794—12816

Identification of mitochondrial-related signature and molecular subtype for the prognosis of osteosarcoma

Xiaokun Zhao¹, Jian Zhang¹, Jiahao Liu¹, Qi Chen¹, Changxiong Cai¹, Xinxin Miao¹, Tianlong Wu^1,², Xigao Cheng^1,^2,³

¹Department of Orthopedics, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, P.R. China
²Jiangxi Key Laboratory of Intervertebral Disc Disease, Nanchang University, Nanchang 330006, Jiangxi, P.R. China
³Institute of Minimally Invasive Orthopedics, Nanchang University, Nanchang 330006, Jiangxi, P.R. China

Received: June 1, 2023Accepted: September 26, 2023Published: November 16, 2023

https://doi.org/10.18632/aging.205143

Copyright: © 2023 Zhao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Mitochondria play a vital role in osteosarcoma. Therefore, the purpose of this study was to investigate the potential role of mitochondrial-related genes (MRGs) in osteosarcoma. Based on 92 differentially expressed MRGs, osteosarcoma samples were divided into two subtypes using the nonnegative matrix factorization (NMF). Ultimately, a univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox analysis were performed to construct a prognostic risk model. The single-sample gene set enrichment analysis assessed the immune infiltration characteristics of osteosarcoma patients. Finally, we identified an osteosarcoma biomarker, malonyl-CoA decarboxylase (MLYCD), which showed downregulation. Osteosarcoma cells proliferation, migration, and invasion were effectively inhibited by the overexpression of MLYCD. Our findings will help us to further understand the molecular mechanisms of osteosarcoma and contribute to the discovery of new diagnostic biomarkers and therapeutic targets.